• Recruiting

NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Updated: May 24


NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

isa-rvd

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM


This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.


Sponsor

Jacob Laubach


Collaborator

Sanofi

 

ClinicalTrials.gov Identifier: NCT04653246

Official Title: Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

First Posted : December 4, 2020


Click here to see details on ClinicalTrials.gov

 

Dexamethasone : National Cancer Institute

Isatuximab : National Cancer Institute

Lenalidomide: National Cancer Institute

Bortezomib : National Cancer Institute

 

Drug: Isatuximab

Drug: Lenalidomide

Drug: Bortezomib Injection

Drug: Dexamethasone

 

Location

United States, Massachusetts



Posts Archive